In early 2021, the Company issued a public offering of Obligasi I Pyridam Farma Tahun 2020 worth Rp. 300 billion, of which the bonds have been listed on Indonesia Stock Exchange on January 14th, 2021.
In early 2021, the Company issued a public offering of Obligasi I Pyridam Farma Tahun 2020 worth Rp. 300 billion, of which the bonds have been listed on Indonesia Stock Exchange on January 14th, 2021.
In addition, in early 2021, the Company has established 4 (four) subsidiaries, namely PT Pyfa Medika Indonesia, PT Mega Inter Distrindo, PT Pyfa Investama Medika, and PT Pyfa Sehat Indonesia.
On December 28th, 2021, the Company acquired the shares of PT Holi Pharma (PT HP) and on December 30th, 2021, the Company increased the capital in PT HP so that the Company’s share ownership in PT HP directly became 99.99% and indirectly became 100% through the share ownership in PT HP by PT Pyfa Sehat Indonesia by 0.01%.
This year, the Company received some awards, including Top 5 Performing Listed Companies: Top 5 Rising Company in the Pandemic Era from Investor Magazine, Indonesia Best Business Transformation 2022 from SWA Magazine, and Top 50 Best of The Best Public Listed Companies from Forbes Indonesia.
